Neurobiology of Aging
Volume 30, Issue 11 , Pages 1728-1736 , November 2009

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

  • Norman R. Relkin

      Affiliations

    • Department of Neurology, The Weill Cornell Medical College, New York, NY, USA
    • ,
  • Paul Szabo

      Affiliations

    • Department of Neurology, The Weill Cornell Medical College, New York, NY, USA
    • Department of Medicine, The Weill Cornell Medical College, New York, NY, USA
    • ,
  • Basia Adamiak

      Affiliations

    • Department of Neurology, The Weill Cornell Medical College, New York, NY, USA
    • ,
  • Tuna Burgut

      Affiliations

    • Department of Neurology, The Weill Cornell Medical College, New York, NY, USA
    • ,
  • Carmen Monthe

      Affiliations

    • Department of Neurology, The Weill Cornell Medical College, New York, NY, USA
    • ,
  • Richard W. Lent

      Affiliations

    • Department of Pathology and Laboratory Medicine, The Weill Cornell Medical College, New York, NY, USA
    • ,
  • Steven Younkin

      Affiliations

    • The Mayo Clinic, Jacksonville, FL, USA
    • ,
  • Linda Younkin

      Affiliations

    • The Mayo Clinic, Jacksonville, FL, USA
    • ,
  • Richard Schiff

      Affiliations

    • Baxter BioScience, Westlake Village, CA, USA
    • ,
  • Marc E. Weksler

      Affiliations

    • Department of Medicine, The Weill Cornell Medical College, New York, NY, USA
    • Corresponding Author InformationCorresponding author at: Weill Medical College, 1300 York Avenue, New York, NY, USA. Tel.: +1 212 794 6478; fax: +1 212 746 6382.

Received 5 August 2007 ,Revised 4 December 2007 ,Accepted 21 December 2007.

References 

  1. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000;6:916–919
  2. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264–2267
  3. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 2002;52:253–256
  4. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 2004;75:1472–1474
  5. Folstein MF, Folstein SE, McHugh PR. Cognitive defect in medical illness. Ann. Intern. Med. 1977;86:827–828
  6. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Ann. Rev. Immunol. 2000;18:739–766
  7. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–1562
  8. Haurum JS. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?. Drug Discov. Today. 2006;11:655–660
  9. Klitgaard JL, Coljee VW, Andersen PS, Rasmussen LK, Nielsen LS, Haurum JS, et al. Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses. J. Immunol. 2006;177:3782–3790
  10. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002;22:6331–6335
  11. Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ, et al. Cloned transchromosomic calves producing human immunoglobulin. Nat. Biotechnol. 2002;20:889–894
  12. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, et al. Insights into the mechanisms of action of anti-beta antibodies in Alzheimer's disease mouse models. FASEB J. 2006;20:2576–2578
  13. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982–985
  14. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 2007;27:233–245
  15. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 2007;204:11–15
  16. O’Nuallain B, Hrncic R, Wall JS, Weiss DT, Solomon A. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J. Immunol. 2006;176:7071–7078
  17. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46–54
  18. Relkin NR, Mujalli D, Shennoy SA, Adamiak B, Weksler ME, Kayed R, et al. IVIg contains antibodies against oligomers and fibrils of beta amyloid. Alzheimer's Dementia. 2007;3:S196
  19. Rodkey LS. Comparative properties of polyclonal and monoclonal antibodies. Methods Mol. Biol. 1995;51:139–150
  20. Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol. Aging. 2006;27:1733–1739
  21. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–177
  22. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996;2:864–870
  23. Wei X, Zhao Z, Ma R, Dodel R, Hampel M, Farlow M, et al. Aβ-antibodies in serum and CSF as potential markers of biological activity in AD. In: Proceedings of the 10th International Conference on Alzheimer's Disease and Related Disorders. 2006;p. 103–108
  24. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002;37:943–948

PII: S0197-4580(07)00497-6

doi: 10.1016/j.neurobiolaging.2007.12.021

Neurobiology of Aging
Volume 30, Issue 11 , Pages 1728-1736 , November 2009

Article Tools

* Image Usage & Resolution